UNSPSC 51401551: Sulazepam

This classification denotes an anxiolytic with the molecular formula C16H13ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NZ779Q5S0W, chemically known as 7-chloro-2,3-dihydro-1-methyl-5-phenyl-1,4-benzodiazepine-2-thione but generally known as sulazepam, which bears US NIH Compound Identifier 17931. European Medicines Agency schedules Sulazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10674MIG. The term SULAZEPAM is an International Non-Proprietary Name.

UNSPSC 51401551 Sulazepam, a Commodity code, does not reflect the work actually being solicited under it in recent state and local procurement. The single opportunity in the recent activity block involves Seminole County, Florida procuring naloxone and safe drug deactivation systems—neither of which are sulazepam—through a competitive IFB. The source shows a mismatch between the nominal code scope and the material being bought.

Seminole County's IFB 60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2026, calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must include all shipping and delivery costs in their bid, comply with drug-free workplace certification and E-Verify requirements, and maintain workers' compensation, commercial general liability, and professional liability insurance. The contract includes a three-month probationary period and a two-year initial term with an optional one-year renewal. Beyond this single opportunity in Florida, the code shows no other recent state and local activity supporting sulazepam procurement or related pharmaceutical acquisitions.